Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

NCT06234423 is registered in ClinicalTrials.gov with OnCusp Therapeutics, Inc. as lead sponsor.

NCT NCT06234423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06234423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Lead sponsor
OnCusp Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 9, 2024
Completion date
October 31, 2027
Enrollment
263 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, solid tumor